StockData
Alaunos Therapeutics, Inc. logo

Alaunos Therapeutics, Inc. (TCRT) stock

TCRTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 4/30
$1.72+0.06 (+3.61%)

Close on Nov 18, 2026Market cap $4.37MP/E –Yield –

Alaunos Therapeutics total assets

Total assets on the balance sheet at the end of each period.

Alaunos Therapeutics's total assets was $1.52M at Jun 30, 2026. For fiscal 2025 it was $2.97M, up 7.7% from the year before. Over ten years it grew -32.6% a year on average. The highest annual figure on record is $153.72M in fiscal 2015.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$2.97M+7.7%
FY2024Dec 31, 2024$2.76M-66.7%
FY2023Dec 31, 2023$8.26M-87.3%
FY2022Dec 31, 2022$64.94M-31.5%
FY2021Dec 31, 2021$94.87M-35.2%
FY2020Dec 31, 2020$146.35M+34.1%
FY2019Dec 31, 2019$109.11M+14.8%
FY2018Dec 31, 2018$95.05M-10.0%
FY2017Dec 31, 2017$105.61M-0.7%
FY2016Dec 31, 2016$106.35M-30.8%
FY2015Dec 31, 2015$153.72M+239.8%
FY2014Dec 31, 2014$45.24M-37.0%
FY2013Dec 31, 2013$71.75M-14.0%
FY2012Dec 31, 2012$83.40M-22.9%
FY2011Dec 31, 2011$108.11M+75.7%
FY2010Dec 31, 2010$61.52M+23.7%
FY2009Dec 31, 2009$49.74M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$1.52M-68.0%
Q1 FY2026Mar 31, 2026$1.88M-11.2%
Q4 FY2025Dec 31, 2025$2.97M+7.7%
Q3 FY2025Sep 30, 2025$3.72M+4.9%
Q2 FY2025Jun 30, 2025$4.74M+1.2%
Q1 FY2025Mar 31, 2025$2.12M-64.9%
Q4 FY2024Dec 31, 2024$2.76M-66.7%
Q3 FY2024Sep 30, 2024$3.55M-81.7%
Q2 FY2024Jun 30, 2024$4.68M-83.2%
Q1 FY2024Mar 31, 2024$6.04M-87.6%
Q4 FY2023Dec 31, 2023$8.26M-87.3%
Q3 FY2023Sep 30, 2023$19.44M-71.1%
Q2 FY2023Jun 30, 2023$27.93M-62.2%
Q1 FY2023Mar 31, 2023$48.64M-42.8%
Q4 FY2022Dec 31, 2022$64.94M-31.5%
Q3 FY2022Sep 30, 2022$67.34M-40.8%
Q2 FY2022Jun 30, 2022$73.93M-30.8%
Q1 FY2022Mar 31, 2022$84.99M-41.9%
Q4 FY2021Dec 31, 2021$94.87M-42.8%
Q3 FY2021Sep 30, 2021$113.76M-37.4%
Q1 FY2021Jun 30, 2021$106.77M-46.2%
Q4 FY2020Dec 31, 2020$146.35M+34.1%
Q3 FY2020Sep 30, 2020$165.89M+40.6%
Q2 FY2020Jun 30, 2020$181.68M+148.3%
Q1 FY2020Mar 31, 2020$198.28M+137.5%
Q4 FY2019Dec 31, 2019$109.11M+14.8%
Q3 FY2019Sep 30, 2019$117.95M+76.6%
Q2 FY2019Jun 30, 2019$73.17M-4.2%
Q1 FY2019Mar 31, 2019$83.50M-4.5%
Q4 FY2018Dec 31, 2018$95.05M-10.0%
Q3 FY2018Sep 30, 2018$66.80M-42.7%
Q2 FY2018Jun 30, 2018$76.38M-39.8%
Q1 FY2018Mar 31, 2018$87.46M-7.4%
Q4 FY2017Dec 31, 2017$105.61M-0.7%
Q3 FY2017Sep 30, 2017$116.56M-0.5%
Q2 FY2017Jun 30, 2017$126.81M-0.9%
Q1 FY2017Mar 31, 2017$94.49M–
Q4 FY2016Dec 31, 2016$106.35M–
Q3 FY2016Sep 30, 2016$117.12M–
Q2 FY2016Jun 30, 2016$128.01M–

More Alaunos Therapeutics figures

See a number that looks wrong?